1. Academic Validation
  2. LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants

LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants

  • Cell Prolif. 2025 May 15:e70060. doi: 10.1111/cpr.70060.
Zhenfei Bi 1 2 Wenyan Ren 1 Hao Zeng 1 Yuanyuan Zhou 3 Jian Liu 1 Zimin Chen 1 Xindan Zhang 1 Xuemei He 1 Guangwen Lu 1 Yuquan Wei 1 Xiawei Wei 1
Affiliations

Affiliations

  • 1 Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
  • 2 Department of Hepatobiliary Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China.
  • 3 Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen, China.
Abstract

Continual evolution of SARS-CoV-2 spike drives the emergence of Omicron variants that show increased spreading and immune evasion. Understanding how the variants orientate themselves towards host immune defence is crucial for controlling future pandemics. Herein, we demonstrate that human cathelicidin LL-37, a crucial component of innate immunity, predominantly binds to the S2 subunit of SARS-CoV-2 spike protein, occupying sites where TMPRSS2 typically binds. This binding impedes TMPRSS2-mediated priming at site S2' and subsequent membrane fusion processes. The mutation N764K within S2 subunit of Omicron variants reduces affinity for LL-37 significantly, thereby diminishing binding capacity and inhibitory effects on membrane fusion. Moreover, the early humoral immune response enhanced by LL-37 is observed in mice against SARS-CoV-2 spike but not Omicron BA.4/5 spike. These findings reveal the mechanism underlying interactions amongst LL-37, TMPRSS2 and SARS-CoV-2 and VOCs, and highlight the distinct mutation for Omicron variants to evade the fusion activity inhibition by host innate immunity.

Keywords

TMPRSS2; LL‐37; SARS‐CoV‐2 infection; omicron variants; spike protein.

Figures
Products
Inhibitors & Agonists
Other Products